Indian stocks: Visit www.stage2stocks.com →

Spyre Therapeutics, Inc.

Stage 3 · Topping · week 5

As of Oct 22, 2026, Spyre Therapeutics is in Stage 3, the topping phase, now in week 5 (since Sep 24, 2026). It closed at $92.33, 15.2% below its 52-week high and above its 200-day average, which is rising.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. More about the company

$92.33
-0.67% today
$8.6B · Mid cap
Market Neutral — Fading

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is SYRE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 25w
S4 28w
S1 14w
S2 48w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S2 6w → S3 9w → S2 25w → S3 11w → S4 4w → S1 3w → S4 1w → S1 4w → S2 1w → S1 3w → S4 28w → S1 14w → S4 1w → S1 1w → S2 48w → S3 4w current
Total tracked: 166 weeks across 17 stage runs.

SYRE among Biotechnology11th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…11SYREStage 3 · wk 598+4.7%
vs 52W High
-15.2%
$22.18 lo$108.92 hi
15.2% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 5
1w13w26w
Week 5, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
29.5%
200 DMA: $71.28 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.60x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+4.7%
3M
-9.6%
6M
+33.3%
YTD
+201.9%
1Y
+297.1%
Scan Membership
Breakout Watch
Latest: 2024-11-13
10 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 5 · Vol 0.60x
2026-10-21S3
Wk 4 · Vol 0.51x
2026-10-20S3
Wk 4 · Vol 1.30x
2026-10-19S3
Wk 4 · Vol 0.98x
2026-10-16S3
Wk 4 · Vol 0.99x
2026-10-15S3
Wk 4 · Vol 0.89x
2026-10-14S3
Wk 3 · Vol 1.28x
2026-10-13S3
Wk 3 · Vol 1.15x
2026-10-12S3
Wk 3 · Vol 0.70x
2026-10-09S3
Wk 3 · Vol 0.90x
2026-10-08S3
Wk 3 · Vol 1.90x
2026-10-07S3
Wk 2 · Vol 2.27x
Moving averages & range
50 DMA
$91.20
200 DMA
$71.28
52W High
$108.92
52W Low
$22.18
5D Low
$79.90
Resistance levels (recent highs)
20d High
$93.19
60d High
$108.92
120d High
$108.92
250d High
$108.92
Next resistance
+0.9%
to 20d High
ROE
-23.0%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 8.5

Spyre Therapeutics: quick answers

What stage is Spyre Therapeutics in?

As of Oct 22, 2026, Spyre Therapeutics (SYRE) is in Stage 3, the topping phase. It entered Stage 3 on Sep 24, 2026 and is in week 5. What the four stages mean

Is Spyre Therapeutics in an uptrend?

Its uptrend has stalled. Spyre Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 29.5% above its 200-day average, which is rising.

How far is Spyre Therapeutics from its 52-week high?

Spyre Therapeutics closed at $92.33 on Oct 22, 2026, 15.2% below its 52-week high of $108.92. Its 52-week low is $22.18.

How has Spyre Therapeutics performed over the past year?

As of Oct 22, 2026, Spyre Therapeutics is up 297.1% over the past year and up 201.9% so far in 2026.

Which sector and industry is Spyre Therapeutics in?

Spyre Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.